Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST.

This suspension comes ahead of a proposed financing transaction, details of which will be announced in a new communication of the Company.

This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume today, June 2, 2026, at approximately 3:30 p.m. CEST, which is the earliest time ADSs are expected to begin trading on the Nasdaq Global Market (9:30 a.m. ET), under the ticker symbol "IVA".